Treating Acute Lymphoblastic Leukemia
in Japan and the
Asia-Pacific Region

Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases

Register Now

Overview

This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute lymphoblastic leukemia (ALL), presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of patients with leukemia, join patient case-based discussions, and interact with experts.

Register Now

Date and Location

October 31, 2025 – November 1, 2025

Chair

Elias Jabbour

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Faculty

Ashish Bajel

Ashish Bajel, MBBS, FRCAP, FRCPA

Peter MacCallum Cancer Center and The Royal Melbourne Hospital, Melbourne, Australia

Shaun Fleming

Shaun Fleming, MBBS(Hons), FRACP, FRCPA

Melbourne Haematology, Richmond, VIC, Australia

Jae Park

Jae Park, MD

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Agenda

This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute lymphoblastic leukemia (ALL) in various countries within Japan and the Asia – Pacific region.

Day 1: Follow interactive presentations and case-based discussions with your peers on the latest updates for first-line assessments and treatments for adults and young adults with ALL, including the role of MRD, risk stratification, and tolerability and feasibility considerations. Engage with the faculty in panel discussions on optimal treatment and how first-line therapy will influence subsequent treatment options. Discuss regional case studies in newly diagnosed ALL with colleagues across Japan and the Asia – Pacific region.

Day 2: Join to learn more about current state-of-the-art approaches for relapsed/refractory (R/R) ALL and the evolving role of transplantation. Discuss regional case studies in R/R ALL with colleagues and discuss challenges with treating elderly and/or frail patients. Interact with faculty during a panel discussion on patient access and regional challenges across Japan and the Asia – Pacific region.

Day 1: Virtual Plenary Sessions

Friday, October 31, 2025

Time (UTC +8) Topic Presenter
8.00 AM – 8.10 AM Welcome and meeting overview; introduction to the voting system Elias Jabbour
8.10 AM – 8.25 AM Latest achievements and developments in ALL Elias Jabbour
8.25 AM – 8.45 AM Review of prognostic and predictive markers in ALL Jae Park
8.45 AM – 9.05 AM Best practices for first-line treatment in ALL Elias Jabbour
9.05 AM – 9.25 AM AYA patients with ALL: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients Shaun Fleming
9.25 AM – 9.35 AM Break  
9.35 AM – 9.55 AM Long-term safety considerations for ALL Jae Park
9.55 AM – 10.25 AM ALL case-based panel discussion for first-line therapy (Bajel/Fleming)

  • Case ALL: Adult low risk
  • Case ALL: Adult high risk (Dr Bajel/Dr Nicol)
  • Case ALL: AYA (Dr Fleming/fellow)
 Panelists: All faculty
10.25 AM – 10.55 AM

Panel discussion: How treatment in first line influences further therapy approaches in ALL

  • Role of HSCT – is it still necessary?
  • Have CAR Ts and bispecifics changed the treatment landscape? If so, how?
  • What does the future look like? Adoption of therapies and evolving standards of care in Japan and the Asia-Pacific region
 (Moderated by Jae Park)
Panelists: All faculty
10.55 AM – 11.00 AM Session close Elias Jabbour

Day 2: Virtual Plenary Sessions

Saturday, November 1, 2025

Time (UTC +8) Topic Presenter
8.00 AM – 8.10 AM Welcome to Day 2 Elias Jabbour
8.10 AM – 8.40 AM Current treatment options for relapsed/refractory (R/R) ALL in fit adults Ashish Bajel
8.40 AM – 9.00 AM Current treatment options for R/R ALL in elderly and frail patients Shaun Fleming
9.00 AM – 9.30 AM Current and future role of transplantation in ALL in Japan and the Asia-Pacific region Ashish Bajel
9.30 AM – 9.40 AM Break  
9.40 AM – 10.15 AM ALL case-based panel discussion for R/R ALL

  • Case ALL: Young (Dr Bajel/fellow)
  • Case ALL: Elderly (Dr Fleming/fellow)
 All faculty
10.15 AM – 10.50 AM

Panel discussion: Open questions in ALL – regional challenges (transplant, CAR T studies, and other)

  • Who are the ideal patients for CAR T therapy, bispecifics, and transplants in your practice?
  • What would be needed to make CAR T therapy available to all of your patients?
  • What would be needed to best position bispecifics in the continuum of care for ALL in adults?
  • How should transplant be strategically combined with the new therapy modalities?
 (Moderated by Shaun Fleming)
Panelists: All faculty
10.50 AM – 11.00 AM Session close Elias Jabbour

Register Now